On June 16, 2023, SQI Diagnostics (SQI), a leader in the science of lung testing, announced that it planned to voluntarily file for bankruptcy.  Upon the legal action being filed the shares of the publicly traded SQI Diagnostics that are held by more than 1,000 shareholders would have become worthless.   Michael Markowski, an analyst who had recommended the shares of SQI interceded to prevent the bankruptcy from being filed.  SQI Diagnostics’ stock symbols:

Canada: SQD.V

US: SQIDF

In his March 30, 2023 ShinyPennyStocks.com “Timing is FINALLY Right for SQI Diagnostics’ Shares” research report Michael Markowski recommended SQIDF shares at a limit price of $0.05.  His rationale for the recommendation was because:

• SQI had submitted several lung testing products to the US. FDA and Canada’s Health Canada regulatory bodies. Regulatory approval for some of the products was granted in 2022.  SQI anticipates that a majority of all of the testing products including its TorDX donor lung testing product will be approved by regulators by the end of 2024.
• SQI’s share price was 90% below its all-time high.

SQI’s proprietary products, upon approval, could potentially value SQI for a billion, equivalent to a share price of $2.00 or above.  Because SQI had a diversified portfolio of change-the-world respiratory products and had other intangibles Mr. Markowski stated “SQI has the best risk reward ratio of any stock that I have ever recommended throughout my 46-year career” in his March 2023 research report.    

After SQI made its bankruptcy announcement, Michael questioned as to why the company’s Board of Directors (BOD) would make such a rash decision.  He contacted the secured creditor, which had sent the foreclosure notice to SQI.  The notice had prompted SQI’s decision to voluntarily seek bankruptcy protection. 

Michael Markowski was surprised to learn that the foreclosing creditor was willing to convert the debt owed by SQI into an equity stake in the company.  Since the creditor was not the catalyst for SQI’s decision to file for bankruptcy he analyzed the public company’s Financial Statements and disclosures.  Mr. Markowski discovered that the majority of SQI’s Board of Directors (BOD) were also secured creditors.  This meant, that in the event of a bankruptcy, the members of the BOD who were secured creditors would continue to have a stake in SQI’s products and intellectual property. 

Armed with this information, Mr. Markowski began his battle to STOP SQI from filing for bankruptcy.  Michael produced a 6/19/23 memo in support of why the bankruptcy should not be filed.  He informed the members of SQI’s BOD that they were self-serving and not acting in the best interests of the company’s minority shareholders.  He cited the conflicts that necessitated a restructuring of SQI’s BOD.  Michael demanded that the conflicted secured lender/directors resign and that his three BOD nominees be elected to SQI’s BOD:

• Dr.David Weill, former Director of the Center for Advanced Lung Disease and Lung and Heart-Lung Transplant Program at Stanford University Medical Center
• David Markowski, former CFO of a publicly traded company and registered investment advisor
• Deborah Markowski, registered investment advisor

In a 6/22/23 follow-up email to the directors Michael Markowski said:

“The bottom line is that SQI Diagnostics will be the cherry on top of the cake when my career ends one way or another.  

1. Biggest stock ever
2.  I will become the most well-known shareholder advocate ever.  The “Ralph Nader” for investors.  

If SQI files for bankruptcy, I will have no choice but to lead the effort for the behalf of all of the shareholders to vigorously pursuit all of the existing board members.  This will enable me to protect and to increase the value of my brand.  Articles have been written about me by every major financial publication throughout my career and Fortune Magazine named me as one of their top 50 investors.    

I guarantee you that lawsuits will be filed against each of the Board members.  Since SQI Diagnostics Inc. has done nothing wrong there will be no need for a class action lawsuit.   

To fund the lawsuits articles will be published about the despicable things that the SQI Board members did and how they did nothing to protect SQI’s common shareholders. My award-winning reporter contact at the Wall Street Journal will love this story.  SQI will become the poster child for why Directors should not be self-serving”.   

Video below is a clip from Michael Markowski’s weekly “Markowski on the Market” Saturday 6/24/23 session.  It’s about the ultimatum that he gave to the SQI Directors. 

On 6/23/23 SQI’s Board of directors relented.  The bankruptcy for SQI was not filed and SQI agreed to restructure its Board of directors.  Mr. Markowski’s director nominees would be elected and would constitute the majority for the SQI Board of Directors.  At July 7, 2023, the details to incorporate the changes were in the process of being worked out.  

Video below is a clip from Michael Markowski’s weekly “Markowski on the Market” Saturday 7/01/23 session.  It’s about the potential price target for SQIDF shares after the SQI-will-not-seek to-file-for-bankruptcy announcement is made.

Video below is a 7/8/23 update on SQI Diagnostics during “Markowski on the Market” weekly Saturday 11:00AM session. 

For updates on SQI Diagnostics subscribe to ShinyPennyStocks.com.  The site offers a free 90- day subscription. 

Visionary analyst and algorithm developer Michael Markowski, is presently in the process to produce an in-depth research update on Investiew (INVU).  He says the ShinyPennyStocks.com (SPS) report will be foundational and on par with his November 12, 2021, “Investview, Ridiculously Undervalued!” report. Michael’s report will reveal his rationale for why the share price could potentially go to $4.03 by 2027, a multiple of 66 times when compared to the $0.0589, 3/22/2022 closing price.    

Michael, who has been in the capital markets since 1977, believes that Investview will vie with Investools to be his best ever stock recommendation throughout his entire career.  His best ever recommendation to date was Investools (Think or Swim) shares at $0.24 in 2003.  

His Investview (INVU) recommendation is amazingly similar to his Investools recommendation.  Both of the bulletin board traded companies were in the investor education business. At 3/21/22, INVU had a double-digit Free Cash Yield which was also the case for Investools in 2003.  Investools shares increased significantly after they became listed on NASDAQ.  The company was subsequently acquired by Ameritrade for cash and shares in 2009.  Ameritrade was then acquired by Schwab in 2019 in an all-stock deal.  The total value (cash and stock) of an Investools share at 12/6/21 as depicted below was $38.04.  The multiple return for an Investools share through 12/6/21 was 119 times.  

The table below depicts that at 12/6/2021, the equivalent value of a share was $38.04, a multiple of 119 times.

To better understand why Michael believes that Investview will rank as his best ever stock recommendation view 4 min, 43 seconds video below.  It’s about his Free Cash Flow Yield (FCY) screen which was utilized to find the two most undervalued stocks (Investools & TRM Corp) in the entire US market in 2003.  TRM shares were recommended at a limit of $0.84 in 2003 and the shares were recommended to be sold at $18.45 in 2004.

This alert is being provided to ShinyPennyStocks.com subscribers since there is a tendency for the price and volume of the shares to surge after a foundational report about a particular company by Mr. Markowski is published.   The chart below is a good example.   It depicts that after the 11/12/21 report was published INVU’s share price surged from under $0.075 to $0.116 and to above SPS’ $0.10 limit price.  The green bars on the bottom right-hand corner of the chart depict that share buy volume was the highest for the entire period covered in the chart.  Note.  Michael Markowski does not hold INVU shares.   ShinyPennyStocks.com’s policy does not allow analysts to take positions in the shares which are recommended.

Michael is now and will continue to aggressively recommend that INVU shares have a 5% of a portfolio weighting.   It’s especially since he has predicted that the Secular Bull market which began in March of 2009, ended on January 4, 2022.  See his “Due to inflation’s effect on PE, S&P 500 to decline 45%” article.  The article explains that a new secular bear, the first since 2000-2009 began at the high.  Based on the prior secular bears which are depicted in the table below the S&P 500 will decline by a minimum of 47% and will have a minimum duration of 8 years.   The asset class which produces all of the long-term capital gains during a secular bear are small companies and those which have low stock prices.

The educational videos below about secular bear markets are highly recommended.  “Proven Secular Bear investing strategies” explains why low-priced shares and shares of small companies are best to own during the new secular bear market which has begun.   “Why the worst performing stocks during a secular bear were always the best performers of the prior secular bull” explains why high priced and blue-chip shares decline during secular bears.